TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact



Transcenta's CEO, Dr. Xueming Qian will be participating in Turning Science Into Business Submit: Cancer research opportunities and advances.

2023 - 11 - 08

Join DDW for its Turning Science into Business Summit: Cancer research opportunities and advances.

This free online event will be hosted by DDW and is sponsored by Taconic Biosciences. It will take place virtually on 16 November 2023 and will also be available on-demand after that date. Please register to receive a recording link after the broadcast.

The 2 hour Summit will outline areas of advancement and opportunity in the cancer research market and will consist of presentations from experts in the field, as well as a panel discussion. Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines and, get to market faster.

Register for free now to hear:

• Qasim Ahmad, CMO, IO Biotech who will discuss The Next Wave of Immunotherapies: Opportunity and Insight. IO Biotech has recently announced new data supporting its therapeutic cancer vaccine.

• Andreas Dreps, SrVP and Global Head of Science, and Muaiad Kittaneh, Senior Director at ICON, on identifying research strategies to get to market faster. ICON has been recognised as one of the world’s leading Contract Research Organisations.

• Joseph R Peterson, CTO & Co-founder, SimBioSys, on Genomics and Personalised Medicine - how genomics is impacting personalised medicine and its future role within cancer drug discovery.

• Dr Raffi Tonikian, Director of Translational Biomarkers at AbCellera, speaking on the topic 'The Therapeutic Antibody Market and Cancer Research.

• An expert panel which will include, Spiro Rombotis, CEO, Cyclacel, Joseph R Peterson, CTO & Co-founder, SimBioSys, Xueming Qian, CEO of Transcenta and Dr Michael Seiler, Vice President of Commercial Products, Taconic Biosciences. They will discuss new drug discovery and development concepts and tools in cancer research.

Register FREE to secure your place: Registration (